Impact of cutaneous disease on patient morbidity and mortality

The burden

Chronic skin disease has a substantial, often underestimated impact on patient quality of life - comparable in magnitude to many serious systemic illnesses when measured by validated quality-of-life instruments, despite skin disease sometimes being perceived (by clinicians and the public) as a lesser, purely cosmetic concern
Conditions such as psoriasis, atopic dermatitis, and acne are consistently shown on validated quality-of-life measures to impair functioning to a degree comparable with major chronic diseases (e.g. some studies show psoriasis's quality-of-life impact comparable to diabetes, cancer, or heart disease)

Visible skin disease affects self-esteem, social functioning, and psychological wellbeing directly (through appearance and stigma) and indirectly (through chronic symptom burden - itch, pain, sleep disruption from conditions like eczema/psoriasis) - the combination of visible and symptomatic burden distinguishes skin disease's quality-of-life impact from many "invisible" chronic diseases

Validated quality-of-life instruments (e.g. the Dermatology Life Quality Index, DLQI) provide a structured, reproducible way to quantify this impact, complementing clinical severity assessment - clinical severity and quality-of-life impact, while related, do not always correlate closely (a modest area of visible facial acne may cause disproportionate distress relative to its objective severity)

Quality-of-life impact should directly inform treatment intensity decisions (not just objective disease severity/extent) - a patient with modest but highly distressing disease may warrant more intensive treatment than the objective severity alone would suggest, and this should be an explicit part of the treatment decision, not an afterthought
Quality-of-life measurement tools like the DLQI exist specifically because clinical severity scoring alone (e.g. percentage body surface area affected) systematically under-captures the true patient-experienced burden of skin disease - both should be assessed together when making treatment decisions

Psoriasis (well-studied quality-of-life burden), atopic dermatitis (sleep disruption from itch), acne (psychological impact - see acne), vitiligo (stigma-related psychological impact)

4 more sections, plus exam facts

Premium unlocks every note across every specialty, and the full exam fact library behind it.